ABOUT US
Neurostech is a medtech company encompassing the development and production of groundbreaking medical devices to improve the delivery of therapeutics for neurological conditions.
Neurostech is specialized in targeting the cerebrospinal fluid (CSF). Our intrathecal precision dosing and biodistribution platform that incorporates deep knowledge of CSF dynamics and bioengineering. The company integrates innovation in neuroscience, precision dosing platforms, and manufacturing capabilities to deliver transformative therapies to patients. This comprehensive approach allows better targeting the pathophysiology of various neurological diseases.
We are a group of scientists and management professionals from the biotech / medtech sector with more than 30 years of experience in either biotech companies or research&innovation centres.
We aim to slow down disease progression and improve the quality of life of patients and families.
OUR MISSION
Our mission is to deliver breakthroughs that change patient’s lives.
Our mission is to deliver breakthroughs that change patient’s lives.
Design, develop and commercialise innovative solutions that can make a difference in the treatment of neurological diseases, through the deployment of new methods to administer drugs more effectively to the central nervous system (CNS).
We are particularly committed to neurodegenerative disorders, a series of prevalent conditions affecting millions of patients worldwide with no curative treatment today.
Rafael Martínez Permuy
CEO & Co-founder
Gabriel Álvarez Menéndez
PhD Chemistry. COO & Co-founder.
Catuxa Prado
PhD Biochemistry. CSO & Co-founder.
Baudilio Zapico Casas
Business Development Director.
María Rodríguez Cañón
PhD Biomedical Engineer.
Ester Pérez Martín
PhD Neurobiology.
Claudia Roces Llorián
Technician.